Clinical development of antivirals against SARS-CoV-2 and its variants

IF 4.8 Q1 MICROBIOLOGY

Current Research in Microbial Sciences Pub Date : 2023-12-02 DOI:10.1016/j.crmicr.2023.100208

Qiaoshuai Lan , Yan Yan , Guangxu Zhang , Shuai Xia , Jie Zhou , Lu Lu , Shibo Jiang

{"title":"Clinical development of antivirals against SARS-CoV-2 and its variants","authors":"Qiaoshuai Lan , Yan Yan , Guangxu Zhang , Shuai Xia , Jie Zhou , Lu Lu , Shibo Jiang","doi":"10.1016/j.crmicr.2023.100208","DOIUrl":null,"url":null,"abstract":"<div><p>The unceasing global spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) calls for the development of novel therapeutics. Although many newly developed antivirals and repurposed antivirals have been applied to the treatment of coronavirus disease 2019 (COVID-19), antivirals showing satisfactory clinical efficacy are few in number. In addition, the loss of sensitivity to variants of concern (VOCs) and lack of oral bioavailability have also limited the clinical application of some antivirals. These facts remind us to develop more potent and broad-spectrum antivirals with better pharmacokinetic/pharmacodynamic properties to fight against infections from SARS-CoV-2, its variants, and other human coronaviruses (HCoVs). In this review, we summarize the latest advancements in the clinical development of antivirals against infections by SARS-CoV-2 and its variants.</p></div>","PeriodicalId":34305,"journal":{"name":"Current Research in Microbial Sciences","volume":"6 ","pages":"Article 100208"},"PeriodicalIF":4.8000,"publicationDate":"2023-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666517423000299/pdfft?md5=f191d01b54fd97314ca9f4c32f74372d&pid=1-s2.0-S2666517423000299-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Research in Microbial Sciences","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666517423000299","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The unceasing global spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) calls for the development of novel therapeutics. Although many newly developed antivirals and repurposed antivirals have been applied to the treatment of coronavirus disease 2019 (COVID-19), antivirals showing satisfactory clinical efficacy are few in number. In addition, the loss of sensitivity to variants of concern (VOCs) and lack of oral bioavailability have also limited the clinical application of some antivirals. These facts remind us to develop more potent and broad-spectrum antivirals with better pharmacokinetic/pharmacodynamic properties to fight against infections from SARS-CoV-2, its variants, and other human coronaviruses (HCoVs). In this review, we summarize the latest advancements in the clinical development of antivirals against infections by SARS-CoV-2 and its variants.

查看原文本刊更多论文

针对 SARS-CoV-2 及其变种的抗病毒药物的临床开发

严重急性呼吸系统综合征冠状病毒 2（SARS-CoV-2）在全球范围内的不断蔓延要求开发新型疗法。尽管许多新开发的抗病毒药物和重新使用的抗病毒药物已被用于治疗 2019 年冠状病毒病（COVID-19），但临床疗效令人满意的抗病毒药物却为数不多。此外，对相关变异株（VOCs）失去敏感性和缺乏口服生物利用度也限制了一些抗病毒药物的临床应用。这些事实提醒我们开发药代动力学/药效学特性更好的更强效、更广谱的抗病毒药物，以对抗 SARS-CoV-2、其变种和其他人类冠状病毒（HCoVs）的感染。在本综述中，我们总结了抗 SARS-CoV-2 及其变种感染的抗病毒药物临床开发的最新进展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Research in Microbial Sciences Immunology and Microbiology-Immunology and Microbiology (miscellaneous)

CiteScore

7.90

自引率

0.00%

发文量

审稿时长

66 days